NICE Initially Against Adding Evrysdi to UK Public Health System

NICE Initially Against Adding Evrysdi to UK Public Health System

295833

NICE Initially Against Adding Evrysdi to UK Public Health System

The initial position of England’s National Institute for Health and Care Excellence (NICE) is to recommend against adding Roche’s Evrysdi (risdiplam) to the list of medications available to spinal muscular atrophy (SMA) patients through the country’s national health service (NHS). Lack of evidence of Evrysdi’s efficacy in babies genetically diagnosed with SMA but not yet showing symptoms (pre-symptomatic) and of its long-term benefits, as well as its high cost, were cited as the main concerns in NICE’s…

You must be logged in to read/download the full post.